API Manufacturing - Emerging Tech Innovations After COVID19 Impact
Major Growth Influencing Factors:
# Increasing incidence of chronic disease
# Technological advancements in API manufacturing
# Growing importance of generics
# Increasing uptake of biopharmaceuticals
# Growing adoption of AI-based tools for drug discovery
# Adoption of organ-on-chip models in drug development
# Focus on precision medicine
# Investments in real-world evidence by pharmaceutical companies
COVID-19 impact on the Active Pharmaceutical Ingredient Market
With the WHO declaring the COVID-19 outbreak a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments that target the infection. In just a few weeks, scientists found a list of molecules that target COVID-19.
Currently, around 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. In this list, there are four promising drugs (Remdesivir, Chloroquine & Hydroxychloroquine, Lopinavir & Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a) that have been repurposed for use against COVID-19.
On March 24, 2020, the WHO announced that it had initiated a global mega trial of the four most promising drugs against COVID-19. Countries are in a global race to develop and mass-produce an efficient vaccine to fight COVID-19. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263
Recent Developments in the Global API Manufacturing Industry:
# In 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.
# In 2020, Novartis (Switzerland) acquired Aspen’s Japanese operations to strengthen its position in the global generics and off-patent medicines market. Novartis also entered into a manufacturing and supply agreement with Aspen.
# In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.
OPPORTUNITY: Highly potent active pharmaceutical ingredients
Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical companies are using small molecules to deliver new therapies. The shift toward HPAPIs has led to the development of a pipeline of more effective medicines that require lower doses. The benefits of HPAPIs, such as their high efficacy, lower therapeutic dose requirement (owing to the selective mode of action), and the ability to bind to specific receptors, can be considered as the major factors responsible for their growing demand among manufacturers as well as customers.
Major Objectives of the Study:
# To define, describe, and forecast the global active pharmaceutical ingredients market based on the type, type of manufacturer, type of synthesis, type of drug, application and region.
# To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities).
# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall active pharmaceutical ingredients market.
# To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
# To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia, and Rest of the World.
# To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
# To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the active pharmaceutical ingredients market.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=263
Geographical Growth Dynamics:
North America was the largest regional market for active pharmaceutical ingredients in 2019.
Geographically, the active pharmaceutical ingredient market is segmented into North America, Europe, Asia, and Rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia Pacific.
The large share of North America in the global market is attributed to , the increasing number of innovative drugs going off-patent and cost-containment measures for healthcare are the key factors supporting the growth of the generic APIs market in this region. Innovative product launches and price increases in North America may, however, restrict the growth of the generic APIs market to a certain extent in the coming years.
Global Leading Companies:
Key players in the active pharmaceutical ingredient market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).
Projected Growth in Revenue Generation:
The global active pharmaceutical ingredient market size is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period.
You can Also Request the New Version of this Report@
https://www.marketsandmarkets.com/RequestNewVersion.asp?id=263